Topic:

R&D

Latest Headlines

Latest Headlines

An international biotech tackles CRISPR gene editing tech with $25M bankroll

A hybrid international biotech upstart with deep U.S. academic roots, a company base in Basel and a plan to grow its research operations in London has landed a $25 million A round to launch another effort at gene editing using CRISPR/Cas9 technology--one of the hottest emerging fields in drug development.

Novartis, GSK deal puts the spotlight on a narrowing R&D focus

The big trend in Big Pharma R&D has been to cut back significantly in key areas where they felt they faced extraordinarily high risks--a particular problem in the central nervous system field, where trial failures have been more the norm than the exception.

Hydrocarbon double-stapling of peptides a new trick in fight against viruses

Researchers have developed a unique delivery mechanism that inhibits the respiratory syncytial virus using double-stapled peptides and nanoparticles. They believe their research has implications for the treatment of other viruses as well.

Kala reels in $22.5M to get its next-gen eye drops into PhIII

Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.

ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials

Detroit-based ProNAi picked up a $59.5 million venture capital round to support its mid-stage DNAi cancer therapy that uses liposomal delivery technology developed by Marina Biotech.

WuXi poaches an AstraZeneca exec to amp up Chinese R&D

Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.

Zafgen tees up an $86M IPO for eye-catching obesity drug

Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology into an $86 million IPO.

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

Sanofi and Pitt join up to test wannabe dengue blockbuster

Sanofi's dengue fever candidate is on the verge of regulatory applications after 20 years in the lab and more than $1.4 billion spent on R&D. Now the pharma giant has forged a new collaboration to help assess the jab's postintroduction effectiveness.

ForSight Vision5 ropes in $15M in Series C financing to develop its intraocular therapy

ForSight Vision5 raised $15 million in a Series C financing and completed enrollment of a Phase II clinical study to support the development of its noninvasive ocular implant therapy for eye diseases.